December 20, 2024
New Delhi, India
Hamps Bio Shares
Hamps Bio shares created a buzz in the market with a blockbuster listing today. The stock debuted at ₹96.90 on BSE SME, marking a 90% premium over its issue price of ₹51. Following its robust listing, the stock hit the 5% upper circuit, further exciting investors.
The Hamps Bio IPO, which opened for subscription on December 13 and closed on December 17, received an overwhelming response, with the subscription status reaching an impressive 1,057 times.
About Hamps Bio Limited
Founded in 2007, Hamps Bio Limited specializes in marketing and distributing pharmaceutical products such as tablets, syrups, capsules, injectables, oils, and nutritional supplements. The company operates in two main segments: Pharmaceuticals and Freeze-dried and Frozen Products.
Their pharmaceutical products are distributed across eight states and union territories in India, while freeze-dried and frozen products reach six countries and 22 states and union territories. The company utilizes a network of over 50 distributors and e-commerce platforms, including Amazon, Flipkart, and Jio Mart, to market its offerings globally.
Hamps Bio IPO Details
The IPO comprised a fresh issue of 12,20,000 equity shares, aggregating ₹6.22 crore. Notably, there was no offer-for-sale component in this IPO. Proceeds from the IPO will be utilized for:
- Acquiring plant and machinery for its FMCG division.
- Enhancing brand visibility and awareness.
- Addressing general corporate expenses.
Marwadi Chandarana Intermediaries Brokers Pvt Ltd acted as the book-running lead manager, while Bigshare Services Pvt Ltd served as the registrar. Pure Broking Private Limited was the market maker for the IPO.
Grey Market Premium (GMP) and Estimated Listing Price
Hamps Bio shares were trading at a GMP of ₹60, as reported by investorgain.com. Based on the IPO price band and the current grey market premium, the estimated listing price was pegged at ₹111, reflecting a potential 117.65% gain.
With its remarkable listing at ₹96.90, the company has already delivered significant returns to investors, setting a strong foundation for its market journey.
Breaking News: Rupee Hits Record Low of ₹85 Against US Dollar
Disclaimer:
CurrencyVeda provides this news article for informational purposes only. We do not offer investment advice or recommendations. Before making any investment decisions, please conduct thorough research, consult with financial experts, and carefully consider your financial situation, risk tolerance, and investment goals. Investing in the stock market carries risks, and it’s essential to make informed choices based on your individual circumstances. CurrencyVeda is not liable for any actions taken based on the information provided in this article.
